Variable outcomes
tumor necrosis, TNF-α
BLOOD, SECONDARY, INSULIN RESISTANCE, TUMOR NECROSIS
Adiponectin levels were the primary outcome measure of this study. Glycated hemoglobin (HbAc1), fasting glucose, insulin, homeostatic model assessment (HOMA) of insulin resistance, lipids, blood pressure, and weight were secondary outcomes.Patients’ clinical history might be accessed via electronic medical records. During the trial, anamnesis, laboratory analysis, and physical exams were gathered prospectively. Physical and anthropometric measurements were taken by competent professionals while the individuals were barefoot and dressed in light clothing. Urine and blood samples were taken before and after the procedures, as well as during the follow-up period. Blood samples were taken in the morning (after a 12-h fast). These samples were allowed to remain at room temperature for 30 min before being centrifuged to separate the serum.An automated analyzer (Cell-Dyn Sapphire and Architect ci16200, Abbott) was used to perform hematimetric and biochemical assays. Insulin was measured using a chemiluminescent immunoassay (Advia Centaur, Siemens). Nephelometry (Immage 8000, Beckman Coulter) was used to measure high sensitive C reactive protein (hs-CRP) and lipoprotein (a) (Lp [a]). All samples were run twice, and the intra- and inter-assay variance coefficients were less than 10%.Levels of adiponectin, interleukin-6 (IL-6), interleukin-1beta (IL-1beta), and tumor necrosis factor-alpha (TNF-α) were measured by an optimized magnetic bead-based multiplex assay for the Luminex® platform (LXSAHM, Bio-Techne R&D Systems, S.L.U.). All analyses were performed according to the manufacturer’s protocols.